Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
Publication Date: July 17, 2018
Diagnosis for NSCLC
Diagnosis for NSCLC
The analysis of PD-L1 expression by an immunohistochemistry (IHC)-based test to determine PD-L1 expression levels is recommended for all patients with newly diagnosed advanced NSCLC.
- Prior to initiation of immunotherapy, tests recommended by the majority of the Task Force included computerized tomography (CT) of the chest, abdomen, and pelvis and thyroid function tests (in addition to routine lab tests).
PD-L1 testing is recommended in newly diagnosed patients with metastatic disease, including those tested for EGFR/ALK/ROS1 mutations whose results are awaited.
678
Table 1. PD-L1 Assay Characteristics and Performance in NSCLC
...1. PD-L1 Assay Characteristics and P...
Treatment for NSCLC
...Treatment for NSCL...
Figure 1. Advanced/Metastatic NSCLC Treatment Algorithm
...Advanced/Metastatic NSCLC Treatment Alg...
...for all newly diagnosed patients is rec...
...ne pembrolizumab monotherapy should be used for pa...
...ts with squamous histology and PD-L1 T...
...th non-squamous, advanced NSCLC and...
...tezolizumab, nivolumab, or pembrolizumab (...
...nts with non-squamous, advanced NSCLC with PD-L1 T...
...mbrolizumab is recommended first-line in...
...b should be used in stage III patients who...
Monitoring for NSCLC
...Monitoring f...
...uring and Monitoring Radiographic ResponseObtai...
...zing, Monitoring and Managing Treat...
...e 2. FDA-approved Programmed Cell...